Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Pulmonary arterial hypertension (PAH): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Pulmonary arterial hypertension: the short answer

The US FDA has approved four medicines on this page for pulmonary arterial hypertension, each for specific patients. Four of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Winrevair, Opsumit, Opsynvi and Uptravi.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
Price: Quote on request.

What is pulmonary arterial hypertension?

Pulmonary hypertension is a serious condition in which blood pressure in the lungs is higher than normal because the pulmonary arteries are damaged, narrowed or blocked. Pulmonary arterial hypertension (PAH) is one type, classed by doctors as Group 1.^[1]

Pulmonary hypertension can develop on its own or because of heart or lung disease, liver disease, sickle cell disease, blood clots or connective tissue disorders. It is usually diagnosed between ages 30 and 60, and family history and genes can play a role.^[1]

PAH is diagnosed by specialists, often with right heart catheterization. In the US, several medicines are approved for adults with PAH, including endothelin receptor antagonists, a prostacyclin receptor agonist, a combination tablet and an activin signaling inhibitor injection.^{[2, 3, 4]}

Pulmonary arterial hypertension in the Gulf

At a Saudi tertiary hospital, 112 of 264 patients who had right heart catheterization from 2009 to 2012 had pulmonary hypertension, and 12 (10.7%) were classified as pulmonary arterial hypertension.^[5]

A genetic study of 48 Saudi patients with idiopathic PAH found possibly harmful variants in known risk genes in one third of patients, a quarter of them in BMPR2.^[6]

US FDA-approved medicines for pulmonary arterial hypertension

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Winrevair (sotatercept-csrk)
FDA-approved for adults with PAH (Group 1) to improve exercise capacity and functional class and reduce the risk of clinical worsening events. It is an injection under the skin every 3 weeks.^[4]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[7, 8]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq, India, Pakistan
Opsumit (macitentan)
FDA-approved for adults with PAH (Group 1) to reduce the risks of disease progression and hospitalization. It is a tablet.^[2]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[7, 8]}
Opsynvi (macitentan and tadalafil)
FDA-approved for chronic treatment of adults with PAH (Group 1) in functional class II to III. It combines macitentan and tadalafil in one tablet.^[9]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[7, 8]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
Uptravi (selexipag)
FDA-approved for adults with PAH (Group 1) to delay disease progression and reduce the risk of hospitalization. It is a tablet.^[3]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[7, 8]}

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[10, 11]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for pulmonary arterial hypertension

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for pulmonary arterial hypertension?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Winrevair, Opsumit, Opsynvi and Uptravi. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Winrevair available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Winrevair?

Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

What is Group 1 pulmonary hypertension?

It is pulmonary arterial hypertension, one of several groups of pulmonary hypertension. The US medicines on this page are approved for Group 1.

Can PAH run in families?

It can. MedlinePlus lists family history and genetics as risk factors, and a Saudi study found risk gene variants in one third of patients tested.

Sources for the last two answers: ^{[4, 2]} ^{[1, 6]}

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

Pulmonary arterial hypertension by country

This page is general health information, not medical advice. It does not replace a consultation with your doctor.